Skip to main content
BIOA
NASDAQ Life Sciences

BioAge Posts Wider Q3 Loss as BGE-102 Trials Advance; QUELL-CV Data Due Q4

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$5.48
Mkt Cap
$254.269M
52W Low
$4.81
52W High
$25.955
52W Position info
14% above low
Off High info
79% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BIOA is trading near its 52-week low of $4.81 (14% above the low).

Summary

BioAge reported a Q3 2026 net loss of $33.5 million, or $0.73 per share, versus $20.2 million ($0.56) a year earlier, driven by R&D spending that jumped to $30.2 million from $18.5 million on BGE-102 trial costs and manufacturing. Collaboration revenue fell to $0.3 million from $2.1 million, largely due to a $1.7 million cumulative catch-up adjustment tied to the September 2026 Novartis amendment. The balance sheet is the key offset: $352.3 million in cash and securities, which management says funds operations through 2029. The near-term driver is QUELL-CV, the Phase 2 dose-ranging study of oral BGE-102 in obesity with elevated inflammation, now fully enrolled at roughly 160 participants, with topline data expected in Q4 2026. QUELL-DME, the Phase 2 diabetic macular edema trial dosed in September, reads out in the second half of 2027, and an APJ agonist IND is targeted by year-end 2026.

At the time of this announcement, BIOA was trading at $5.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $254.3M. The 52-week trading range was $4.81 to $25.96. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BIOA - Latest Insights

BIOA
Nov 05, 2026, 4:40 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.48
Real-time Price: $5.55 info
Change: +$0.070 (+1%) info
Market Cap: $254.269M info
BIOA
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $9.75
Real-time Price: $5.55 info
Change: -$4.20 (-43%) info
Market Cap: $254.269M info
BIOA
Aug 05, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.98
Real-time Price: $5.55 info
Change: -$5.43 (-49%) info
Market Cap: $254.269M info
BIOA
Aug 05, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.98
Real-time Price: $5.55 info
Change: -$5.43 (-49%) info
Market Cap: $254.269M info
BIOA
Jul 31, 2026, 1:24 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $9.58
Real-time Price: $5.55 info
Change: -$4.03 (-42%) info
Market Cap: $254.269M info